Skip to content
Head to head

ADMA Biologics vs Vertex Pharmaceuticals

Side-by-side on the measures that matter, with a plain-English read. Full detail: ADMA · VRTX

Updated 8 minutes ago

1-year performance, rebased to 100

ADMA -14.6%VRTX +18.7%
Vertex Pharmaceuticals edges it on the scoreable measures. Vertex Pharmaceuticals has the highest Quant Rating (68); Vertex Pharmaceuticals has done best over the past year (+22%); Vertex Pharmaceuticals earns the most per share.
ADMAVRTX
Snapshot
SectorBiotechnologyBiotechnology
Last price13.17515.02
Change today-1.27%-1.08%
1-year return-19.5%+22.0%
Market cap$2.92B$130.58B
52-week range7.21 – 20.46412.27 – 568.67
Valuation
P/E (TTM)17.1033.14
P/E percentile, own 5-yr range69th99th
P/B6.666.25
Dividend yield0.00%0.00%
Profitability & growth
EPS (TTM)0.6015.32
Net profit (TTM)$133.11M$3.88B
Revenue (TTM)$519.15M$12.95B
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)+5.1%+11.8%
Gross margin68.5%85.5%
Operating margin44.9%33.1%
Net margin35.1%30.7%
Free cash flow (TTM)$132.60M$3.20B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership89.9%96.8%
Insider activity (12mo)23 buy / 25 sell28 buy / 22 sell
Short interest (% of float)8.1%1.9%
Analyst consensus67% buy / 33% hold (3)95% buy / 5% hold (21)
Analyst price target$17 (+27%)$624 (+21%)
StockVane view
StockVane Quant RatingD (22)C (68)
Company
Employees6476,400
Founded20041989

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.